Safety and efficacy of dual versus triple antithrombotic therapy (DAT vs TAT) in patients with atrial fibrillation following a PCI: a systematic review and network meta-analysis.
Renad M AltoukhiReema A AlshouimiShahad M Al RammahMohammed Y AlzahraniAbdulaali R AlmutairiAbdulmajeed M AlshehriOsamah M AlfayezMajed S Al YamiOmar A AlmohammedPublished in: BMJ open (2020)
The DAT regimens are as safe and effective as TAT regimens. However, ranking probabilities for the best option in the selected outcomes can be used to guide the selection among these agents based on different patients' conditions.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- atrial fibrillation
- chronic kidney disease
- coronary artery disease
- peritoneal dialysis
- acute myocardial infarction
- acute coronary syndrome
- prognostic factors
- percutaneous coronary intervention
- stem cells
- type diabetes
- metabolic syndrome
- patient reported outcomes
- antiplatelet therapy
- mesenchymal stem cells
- st segment elevation myocardial infarction
- weight loss